What can be expected from the Translational Regenerative Medicine market? Which areas are going to grow at the fastest rates? This Visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects there.
Our 285-page report provides 170 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the whole of translational regenerative medicine market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.
Forecasts from 2016-2026 and other analyses show you commercial prospects Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter’s Five Forces analysis) and commercial developments.
See revenue forecasts for the leading submarkets and indications How will submarkets perform to 2026? Our study forecasts revenues in the following Translational regenerative medicine submarkets: • Stem Cell Therapies • Tissue Engineering • Gene Therapies
See revenue forecasts for some the leading products in the market How will leading drug perform to 2026? Our study forecasts revenues for a number of leading products in the translational regenerative medicine market including: • Osteocel Plus • Trinity ELITE • TEMCELL /Prochymal • Apligraf • Dermagraft • ReCell • Neovasculgen • Glybera (alipogene tiparvovec) • IMLYGIC (talimogene laherparepvec)
See revenue forecasts for the leading regional markets How will leading national and regional markets perform to 2026? Our study forecasts revenues in national markets including products, including: • US • Europe • Asia-Pacific • Rest of World
Leading companies and potential for market growth Overall revenue for the Translational Regenerative Medicine market will reach $12.1bn in 2020, our work forecasts. We predict strong revenue growth through to 2026. Advances in cellular and tissue research, an improving regulatory landscape, strong support from governments in multiple regions and the launch of several new therapies in areas of unmet clinical need will drive sales to 2026.
Our work analyses the key companies in the market. See Visiongain’s analysis of 16 leading companies, including these: • Alphatec Spine • Anterogen • Athersys • Avita Medical • AxoGen • Medipost • Mesoblast • NuVasive • Ocata Therapeutics • Organogenesis • Osiris Therapeutics • Pharmicell • Regenersys • TiGenix • UniQure • Vericel Corporation
A company profile gives you the following information where available: • Discussion of a company’s activities and outlook • Historic revenue, analysis and discussion of company performance over the past 5 years • Analysis of major products currently on the market • Acquisitions and strategic partnerships
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
What issues will affect translational regenerative medicine industry? Our new report discusses issues and events affecting the translational regenerative medicine market. You will find discussions, including qualitative analyses: • Highly diverse market needing strong knowledge of key therapeutic indications • Changing regulatory landscape challenging new entrants and major market players alike • Emerging therapies with the potential to reshape the market
You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.
How the Translational Regenerative Medicine: Market Prospects 2016-2026 report helps you In summary, our 285-page report gives you the following knowledge: • Revenue forecasts to 2026 for the Translational Regenerative Medicine market – discover the industry’s prospects, finding promising places for investments and revenues • Revenue forecasts to 2026 for each major submarket – discover prospects for leading translational regenerative medicine products in the following areas: stem cell therapies, tissue engineering and gene therapy. • Revenue forecasts to 2026 for 9 of the leading products in the Translational Regenerative Medicine market – discover prospects for leading translational regenerative medicine products including: Osteocel Plus, Trinity ELITE, TEMCELL /Prochymal, Apligraf, Dermagraft, ReCell, Neovasculgen, Glybera (alipogene tiparvovec) and IMLYGIC (talimogene laherparepvec) • Revenue forecasts to 2026 for one leading national market and two leading regional markets – US, Europe, Asia-Pacific and Rest of World • Assessment of 16 leading companies – analysis of products, revenue, mergers & acquisitions, sales by region, therapeutic area and product type • Discussion of what stimulates and restrains companies and the market • Prospects for established firms and those seeking to enter the market
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain’s study is for everybody needing commercial analyses for the translational regenerative medicine market and leading companies. You will find data, trends and predictions. Please order our report now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Global Translational Regenerative Medicine: Market Overview 1.2 Global Translational Regenerative Medicine Market Definition and Segmentation 1.3 Why You Should Read This Report 1.4 How This Report Delivers 1.5 Key Questions Answered By This Analytical Report 1.6 Who Is This Report For? 1.7 Methodology 1.8 Frequently Asked Questions (FAQ) 1.9 Associated Reports 1.10 About Visiongain
2. An Introduction To Translational Regenerative Medicine 2.1 What Is Regenerative Medicine? 2.1.1 Translational Regenerative Medicine – From Bench to Bedside 2.2 Translational Regenerative Medicine – Market Breakdown 2.2.1 Stem Cell Therapy – Marketable Differentiation And Specialisation 2.2.1.1 How Embryonic Stem Cells (ESCs) Entered The Fray 2.2.1.2 Classifying Stem Cells by Potency 2.2.1.3 Stem Cells Categories: ESCs, SSCs, iPSCs 2.2.1.4 Parthenogenetic Stem Cells: Ethical ESC-Like Cells? 2.2.1.5 Autologous vs. Allogeneic Stem Cells: Towards Universal Stem Cell Products? 2.2.2 Tissue Engineering – In Vitro Manipulation for Therapeutic Purposes 2.2.3 Gene Therapies 2.2.3.1 Harnessing Infectivity: Viral Vectors in Gene Therapy 2.3 Other Approaches to Regenerative Medicine 2.3.1 Small Molecules and Proteins – Scaffold-Based Delivery of Signalling Molecules 2.3.2 Cosmetic Applications of Regenerative Medicine 2.4 Regulation of Regenerative Medicine 2.4.1 Regulation of Regenerative Medicine Products in Europe 2.4.2 Regulation of Regenerative Medicine Products in the US 2.5 The Phases of Clinical Trials 2.6 Market Definition 2.6.1 Products Excluded from the Report
3. Translational Regenerative Medicine Market, 2016-2026 3.1 Global Translational Regenerative Medicine: Market Overview 3.1.1 Segments within the Global Translational Regenerative Medicine Market 3.2 The Global Translational Regenerative Medicine Market in 2014 and 2015 3.3 Global Translational Regenerative Medicine: Market Forecast 2016-2026 3.3.1 Market Sectors That Will Drive Translational Regenerative Medicine Growth 3.3.2 Global Translational Regenerative Medicine Market - Changing Market Shares By Sector 2016-2026
4. Stem Cell Therapies: Leading Applications, 2016-2026 4.1 The Global Market for Stem Cell Therapies, 2014 and 2015 4.1.1 Stem Cell Therapies: Currently Available Therapies 4.1.2 Haematopoietic Stem Cell Transplantation (HSCT) 4.1.2.1 HSCT for the Treatment of Multiple Sclerosis – A Possible Cure? 4.1.3 Stem Cell Orthobiologics 4.2 Stem Cell Therapies: Global Market Forecast 2016-2026 4.3 AlloStem (AlloSource) 4.4 Osteocel Plus (NuVasive) 4.4.1 Osteocel Plus: Sales Forecast 2016-2026 4.5 Trinity ELITE and Trinity Evolution (Orthofix) 4.5.1 Trinity ELITE and Trinity Evolution: Sales Forecast, 2016-2026 4.6 PureGen (AlphaTec Spine) 4.7 Other Approved Stem Cell Therapy Products, 2015 4.7.1 Cartistem (Medipost) 4.7.2 Cupistem (Anterogen) 4.7.3 Hearticellgram-AMI (Pharmicell) 4.7.4 TEMCELL/ Prochymal/ Remestemcel-L (Mesoblast) 4.7.4.1 TEMCELL/ Prochymal (Remestemcel-L): Sales Forecast 2016-2026 4.8 Development Pipeline for Stem Cell Therapies, 2016-2026 4.8.1 Late-Stage Pipeline for Stem Cell Therapies, 2015 4.8.1.1 StemEx and NiCord (Gamida Cell) 4.8.1.1.1 StemEx Shows Improved Survival at 100 Days – but FDA Wants Another Clinical Trial 4.8.1.2 Copper Chelator Based Technology 4.8.1.3 NiCord 4.8.1.3.1 NiCord: Gamida Cell Reaches Agreement on Phase 3 Design Outline with the FDA and EMA 4.8.1.3.2 NAM Technology Platform 4.8.1.4 Mesenchymal Precursor Cell Therapies (Mesoblast) 4.8.1.5 Adult Autologous CD34+ Cells (Baxter) 4.8.1.6 MyoCell (U.S. Stem Cell Inc.) 4.8.1.7 Cx601 (TiGenix) 4.8.1.8 Adipose-Derived Stem Cells (Cytori Therapeutics) 4.8.1.9 Stempeucel (Stempeutics Research) 4.8.1.10 C-Cure (Cardio3 BioSciences) 4.8.1.11 Other Late-Stage Stem Cell Therapies 4.8.2 Diabetes and Stem Cell Therapy 4.8.2.1 Mesenchymal Precursor Cells (Mesoblast) 4.8.2.2 VC-01 (ViaCyte Inc) 4.8.2.2.1 Clinical Development Efforts for VC-01 for the Treatment of Diabetes 4.8.3 Cardiovascular Disease and Stem Cell Therapy 4.8.3.1 Endometrial Regenerative Cells (MediStem, Intrexon) 4.8.3.2 AMR-001 (Caladrius Biosciences) 4.8.3.3 CAP-1002 (Capricor) 4.8.4 Stem Cell Therapy in Cancer 4.8.4.1 CLT-008 (Cellerant Therapeutics) 4.8.4.2 OncoCyte/BioTime – Targeting Cancer with Gene and Stem Cell Therapy 4.8.5 Stem Cell Therapy for Central Nervous System (CNS) Conditions 4.8.5.1 NurOwn (BrainStorm Cell Therapeutics) 4.8.5.1.1 Clinical Development Efforts for NurOwn, 2015 4.8.5.2 NSI-566 (Neuralstem) 4.8.5.3 NSI-189 (Neuralstem) 4.8.5.4 MultiStem (Athersys) 4.8.5.5 PDA-001 (Cenplacel-L, Celgene) 4.8.5.6 ALD-401 (Cytomedix) 4.8.5.7 ReN001 (ReNeuron) 4.8.6 Stem Cell Therapy for Eye Diseases 4.8.6.1 MA09-hRPE (Ocata Therapeutics) 4.8.6.2 HuCNS-SC (StemCells Inc.) 4.8.6.3 Collaboration And License Agreement Between Pfizer And The London Project to Cure Blindness 4.9 Stem Cells Therapy Market: Drivers and Restraints 2016-2026
5. Tissue Engineering Therapies: Leading Applications, 2016-2026 5.1 The Global Market for Tissue Engineered Therapies, 2014 and 2015 5.1.1 Tissue Engineering Therapies: Currently Available Therapies 5.2 Tissue Engineering Therapies: Global Market Forecast 2016-2026 5.3 Tissue Engineering in Wound Repair and Healing 5.3.1 Apligraf (Organogenesis) 5.3.1.1 Apligraf: Historical Sales Analysis 5.3.1.2 Apligraf: Sales Forecast 2016-2026 5.3.2 BioDfence and BioDfactor (BioD) 5.3.3 CureXcell (MacroCure) 5.3.4 Dermagraft (Organogenesis) 5.3.4.1 Dermagraft (Organogenesis): Sales Forecast 2016-2026 5.3.5 Epicel (Vericel) 5.3.6 Grafix (Osiris Therapeutics) 5.3.7 MySkin and CyroSkin (Regenerys) 5.3.8 ReCell (Avita Medical) 5.3.8.1 ReCell (Avita Medical): Sales Forecast 2016-2026 5.4 Tissue Engineering for Cartilage Repair 5.4.1 Autologous Chondrocyte Implantation (ACI) 5.4.2 Carticel (Vericel Corp.) 5.4.3 ChondroCelect (TiGenix, Sobi Partners) 5.4.4 DeNovo NT (Zimmer) 5.4.5 MACI (Vericel Corp.) 5.5 Other Available Tissue Engineering Therapies 5.5.1 Autologous Cultured Cell and Tissue Products (Japan Tissue Engineering Co.) 5.5.2 Gintuit (Organogenesis) 5.5.3 LAVIV (azficel-T), (Fibrocell Science) 5.5.4 Acellular Tissue Engineering Products 5.6 Tissue Engineering: Development Pipeline, 2016-2026 5.6.1 Pipeline Products for Autologous Chondrocyte Implantation 5.6.2 Tissue Engineering for Skin 5.6.3 Tissue Engineering for Liver Diseases 5.6.3.1 Extracorporeal Bio-Artificial Liver Therapy (Vital Therapies) 5.6.4 Tissue Engineering for Cardiovascular Disease 5.6.5 Tissue Engineering for Eye Diseases 5.7 Future Prospects for Organ Transplantation and Tissue Engineering 5.8 Tissue Engineered Products Market: Drivers and Restraints 2016-2026
6. Gene Therapies: Leading Applications, 2016-2026 6.1 The Global Market for Gene Therapies, 2014 and 2015 6.2 Gene Therapies: Global Market Forecast 2016-2026 6.3 Currently Available Gene Therapy Products 6.3.1 Gendicine (Benda Pharmaceutical) 6.3.2 Oncorine (Shanghai Sunway Biotech) 6.3.3 Neovasculgen (Human Stem Cells Institute) 6.3.3.1 Neovasculgen (HSCI): Sales Forecast 2016-2n 7.6.5.4 Accelerating Approvals of Regenerative Medicine Products in Japan 7.6.6 India: An Emerging Market for Regenerative Medicine 7.6.6.1 Efforts in Stem Cell Research in India 7.6.6.2 Unclear Guidelines Hindering Progression of Gene Therapy Research in India 7.6.7 South Korea: First to Approve Stem Cell Treatments 7.6.7.1 A Regeneration In South Korea’s Stem Cell Research Efforts 7.7 Rest of the World: Regenerative Medicine Conquering New Territories and Booming 7.7.1 Rest of the World Regenerative Medicine Market: Market Forecast 2016-2026
8. The Leading Companies in the the Translational Regenerative Medicine Market, 2016-2026 8.1 Translational Regenerative Medicine: A Hotbed for Innovation 8.2 Alphatec Spine 8.2.1 Alphatec Spine: Financial and Performance Analysis, 2009-2014 8.2.2 Alphatec Spine’s Shifting Focus from Regenerative Medicine to Medical Devices 8.3 Anterogen 8.3.1 Anterogen: Pipeline Analysis, 2015 8.4 Athersys 8.4.1 Athersys: Financial and Performance Analysis, 2010-2014 8.4.2 Athersys: Pipeline Analysis, 2015 8.4.2.1 MultiStem Technology – Potential Treatment for a Range of Diseases 8.5 Avita Medical 8.5.1 Avita Medical: Historical Financial and Performance Analysis, 2013-2015 8.5.2 Avita Medical: Regenerative Medicine Portfolio, 2015 8.5.3 Avita Medical: Pipeline Analysis, 2015 8.6 AxoGen 8.6.1 AxoGen: Historical Financial and Performance Analysis, 2010-2014 8.6.2 AxoGen: Regenerative Medicine Portfolio, 2015 8.6.3 AxoGen: Pipeline Analysis, 2015 8.8 Medipost 8.7.1 Medipost: Historical Financial and Performance Analysis, 2010-2014 8.7.2 Medipost: Regenerative Medicine Portfolio, 2015 8.7.3 Medipost: Pipeline Analysis, 2015 8.8 Mesoblast 8.8.1 Mesoblast Product Portfolio, 2015 8.8.2 Mesoblast: Historical Financial and Performance Analysis, 2010-2015 8.8.3 Mesoblast: Pipeline Analysis, 2015 8.8.3.1 NeoFuse 8.8.3.2 Chondrogen 8.8.3.3 Prochymal / TEMCELL 8.8.3.4 Other Recent Pipeline Acquisitions by Mesoblast 8.9 NuVasive 8.9.1 NuVasive Product Portfolio, 2015 8.9.2 NuVasive: Historical Financial and Performance Analysis, 2009-2013 8.9.3 NuVasive: Pipeline Analysis, 2015 8.10 Ocata Therapeutics 8.10.1 Ocata Therapeutics: Historical Financial and Performance Analysis, 2009-2014 8.10.2 Ocata Therapeutics: Pipeline Analysis, 2015 8.10.2.1 Retinal Pigment Epithelial Cell Therapy 8.10.3 Ocata’s Other Therapeutic Platforms 8.11 Organogenesis 8.11.1 Organogenesis RM Portfolio, 2015 8.11.2 Organogenesis: Pipeline Analysis, 2015 8.12 Osiris Therapeutics 8.12.1 Osiris Therapeutics: RM Portfolio, 2015 8.12.2 Osiris Therapeutics: Historical Financial and Performance Analysis, 2010-2014 8.12.3 Osiris Therapeutics: Pipeline Analysis, 2015 8.13 Pharmicell 8.13.1 Pharmicell: Historical Financial and Performance Analysis, 2010-2014 8.13.2 Pharmicell: Pipeline Analysis, 2015 8.14 Regenerys 8.14.1 Regenerys: RM Portfolio, 2015 8.14.2 Regenerys: Pipeline Analysis, 2015 8.15 TiGenix 8.15.1 TiGenix: Historical Financial and Performance Analysis, 2011-2014 8.15.2 TiGenix: Pipeline Analysis, 2015 8.16 UniQure 8.16.1 UniQure: Pipeline Analysis, 2015 8.17 Vericel Corporation (Formerly Aastrom Biosciences, Inc.)
9. Qualitative Analysis of the Translational Regenerative Medicine Market, 2015 9.1 Market Factors Influencing the Translational Regenerative Medicine Market 9.2 SWOT Analysis of the Translational Regenerative Medicine Market, 2016-2026 9.3 Strengths 9.3.1 Improvements in Regulatory Frameworks 9.3.2 Advancements in General Cellular and Tissue Research Aiding Regenerative Medicine 9.3.3 Strong Support from Governments in Multiple Regions 9.3.4 Increasing Ease of Product Commercialisation and Market Access 9.4 Weaknesses 9.4.1 The High Price of Translational Regenerative Medicine Products May Restrain Market Growth 9.4.2 Lack of Funding from Venture Capital 9.4.3 The Intrinsic Lack of Standardisation is a Burden to Scaling up Manufacturing 9.4.4 Successful Commercialisation of TRM Products Requires New Business Models 9.5 Opportunities 9.5.1 3D Bioprinting and Other Technologies May Enable Rapid Scale-Up 9.5.2 Medical Tourism May Stimulate Standardisation and Drive Market Growth 9.5.3 Disruptive Translational Regenerative Medicine Therapies Can Create New Markets 9.6 Threats 9.6.1 Ethical Concerns Limiting R&D in Regenerative Medicine 9.6.2 Difficulty Establishing an Evidence Base For Long-Term Efficacy Of TRM Therapies 9.6.3 Rate of Scientific Progress – A Major Determinant of TRM Market Growth 9.6.4 Restraints on Reimbursement May Slow Growth 9.7 Porter’s Five Force Analysis of the Translational Regenerative Medicine Market, 2016-2026 9.7.1 Threat of New Entrants 9.7.2 Threat of Substitutes 9.7.3 Power of Suppliers 9.7.4 Power of Buyers 9.6.5 Rivalry among Competitors
10. Research Interviews 10.1 Interview with Dr Cynthia Bamdad, PhD, CEO of Minerva Biotechnologies 10.1.1 Naïve State Stem Cells Could Significantly Impact the Regenerative Medicine Market 10.1.2 On Relationships between Big Pharma and Smaller Biotech Companies in the Translational Regenerative Market 10.1.3 Growth of Minerva Biotechnologies 10.1.4 Possible New Commercial Applications for Regenerative Medicine 10.1.5 Translational Regenerative Medicine in Emerging Markets 10.1.6 iPS Cells – The Future of Stem Cell Therapies? 10.1.7 On Drivers and Restraints in the Translational Regenarative Medicine Market in 2016 10.2 Interview with Dr Yael Margolin, CEO of Gamida Cell Ltd. 10.2.1 Progress of NiCord in the Blood Cancer Indication 10.2.2 On Drivers and Restraints in the Blood Cancer Market in 2015 10.2.3 Growth of Gamida Cell Ltd.
11. Conclusion 11.1 Overview of Current Market Conditions and Market Forecast, 2014-2026 11.2 Leading Regenerative Medicine Segments in 2014 and 2015 11.3 Leading Regions in the Translational Regenerative Medicine Market in 2014 And 2015 11.4 Future Outlook for the Various Sectors within TRM, 2016-2026 11.5 R&D Pipeline Products Crucial to Future Market Growth 11.6 What Does the Future Hold for Regenerative Medicine?
12. Glossary
Appendices Associated Visiongain Reports Visiongain Report Sales Order Form Appendix A About Visiongain Appendix B Visiongain report evaluation form
List of Tables Table 1.1 Global Translational Regenerative Medicine Market: Market Forecast ($m, AGR% and CAGR%) by Segment, 2014-2020 (Altered Data) Table 1.2 Global Translational Regenerative Medicine Market: Market Forecast ($m, AGR% and CAGR%) by Segment, 2020-2026 (Altered Data) Table 2.1 European Union Definitions of Regenerative Medicine Products, 2015 Table 2.2 Potency and Source of Stem Cells, 2016 Table 2.3 Germ Layers and Their Associated Types of Cells and Organs, 2016 Table 2.4 Major Types Of Stem Cells and Their Properties, 2016 Table 2.5 Terminology For Stem Cell Donor-Types, 2016 Table 2.6 Clinical Trial Phases, 2016 Table 3.1 The Global Translational Regenerative Medicine Market: Revenue ($m) and Market Shares (%) by Sector, 2014 and 2015 Table 3.2 The Global Translational Regenerative Medicine Market: Market Forecast ($m, AGR% and CAGR%) by Sector, 2014-2020 Table 3.3 The Global Translational Regenerative Medicine Market: Market Forecast ($m, AGR% and CAGR%) by Sector, 2020-2026 Table 3.4 The Global Translational Regenerative Medicine Market Forecast: CAGR (%) by Sector, 2014-2020, 2020-2026 and 2014-2026 Table 3.5 The Global Translational Regenerative Medicine Market: Revenue ($m) by Sector, 2014, 2020 and 2026 Table 3.6 The Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2014, 2020 and 2026 Table 4.1 Selected Stem Cell Products Currently Available On The Market, 2015 Table 4.2 Stages of Osteogenesis, 2015 Table 4.3 Global Stem Cell Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 4.4 Global Stem Cell Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026 Table 4.5 Osteocel Plus Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026 Table 4.6 Osteocel Plus Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026 Table 4.7 Trinity ELITE Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 4.8 Trinity ELITE Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026 Table 4.9 TEMCELL / Prochymal Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 4.10 TEMCELL / Prochymal Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026 Table 4.11 Stem Cell Therapy Pipeline: Therapies in Late-Stage Clinical Trials, 2015 Table 5.1 Selected Tissue Engineering Products Currently Available on the Market, 2015 Table 5.2 Global Tissue Engineering Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 5.3 Global Tissue Engineering Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026 Table 5.4 Apligraf Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 5.5 Apligraf Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026 Table 5.6 Dermagraft Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 5.7 Dermagraft Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026 Table 5.8 ReCell Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 5.9 ReCell Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026 Table 5.10 Vital Therapies: Extracorporeal Bio-Artificial Liver Therapy Clinical Trials, 2015 Table 6.1 Currently Available Gene Therapy Products, 2015 Table 6.2 Global Gene Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 6.3 Global Gene Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026 Table 6.4 Neovasculgen Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 6.5 Neovasculgen Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026 Table 6.6 Glybera Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 6.7 Glybera Sales Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026 Table 6.8 Amgen: Gene Therapy Clinical Trials, 2015 Table 6.9 Talimogene Laherparepvec (IMLYGIC) Sales Forecast ($m, AGR% and CAGR%), 2014-2026 Table 6.10 Talimogene Laherparepvec (IMLYGIC) Sales Forecast ($m, AGR% and CAGR%), 2014-2026 Table 6.11 Gene Therapy Pipeline: Therapies in Late-Stage Clinical Trials, 2015 Table 6.12 Advantegene: Gene Therapy Clinical Trials, 2015 Table 6.13 Spark Therapeutics: Gene Therapy Clinical Trials, 2015 Table 6.14 Recent Developments in Gene Therapy for Use in Diabetes Table 6.15 Gene Therapy Products in the Development Pipeline for Neurological Diseases, 2015 Table 7.1 The Global Translational Regenerative Medicine Market: Market Size ($m) and Market Share (%) by Region, 2014 and 2015 Table 7.2 Global Translational Regenerative Medicine Market: Market Forecast ($m), AGR (%) and CAGR (%) by Region, 2014-2020 Table 7.3 Global Translational Regenerative Medicine Market: Market Forecast ($m), AGR (%) and CAGR (%) by Region, 2020-2026 Table 7.4 Global Translational Regenerative Medicine Market: CAGR (%) by Region, 2014-2020, 2020-2026, 2014-2026 Table 7.5 Global Translational Regenerative Medicine Market: Market Share (%) by Region, 2014, 2020 and 2026 Table 7.6 US Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2014, 2020 and 2026 Table 7.7 US Translational Regenerative Medicine Market Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 7.8 US Translational Regenerative Medicine Market Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026 Table 7.9 European Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2014, 2020 and 2026 Table 7.10 European Translational Regenerative Medicine Market Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 7.11 European Translational Regenerative Medicine Market Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026 Table 7.12 Asia-Pacific Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2014-2026 Table 7.13 Asia-Pacific Translational Regenerative Medicine Market Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 7.14 Asia-Pacific Translational Regenerative Medicine Market Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026 Table 7.15 Rest of the World Translational Regenerative Medicine Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2014-2026 Table 7.16 Rest of the World Translational Regenerative Medicine Market Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 7.17 Rest of the World Translational Regenerative Medicine Market Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026 Table 8.1 Alphatec Spine: Historical Sales ($m) and Operating Profit / Loss ($m), 2009-2014 Table 8.2 Alphatec Spine: Regenerative Medicine Clinical Trials, 2015 Table 8.3 Anterogen: Regenerative Medicine Clinical Trials, 2015 Table 8.4 Athersys: Historical Sales ($m) 2010-2014 Table 8.5 Athersys: Historical Expenditure and Losses ($m) 2010-2014 Table 8.6 Athersys: Regenerative Medicine Clinical Trials, 2015 Table 8.7 Avita Medical: Historical Sales ($m, AUD m) and Net Loss ($m, AUD m), 2013-2015 Table 8.8 Avita Medical: Regenerative Medicine Clinical Trials, 2015 Table 8.9 AxoGen: Historical Sales ($m) and Net Loss ($m), 2010-2014 Table 8.10 AxoGen: Regenerative Medicine Clinical Trials, 2015 Table 8.11 Medipost: Historical Sales ($m, mil.KRW), Net Income ($m, mil.KRW) and Revenue Growth (%) 2010-2014 Table 8.12 Medipost: Historical Sales (mil.KRW), Net Income ($m, mil.KRW) and Revenue Growth (%) 2010-2014 Table 8.13 Medipost: Regenerative Medicine Clinical Trials, 2015 Table 8.14 Mesoblast: Historical Sales ($m, AUD m), 2010-2015 Table 8.15 Mesoblast: Regenerative Medicine Clinical Trials, 2015 Table 8.16 NuVasive: Historical Sales ($m) and Net Income (Profits and Losses) ($m), 2009-2014 Table 8.17 NuVasive: Regenerative Medicine Clinical Trials, 2015 Table 8.18 Ocata Therapeutics: Historical Sales ($thousand) and Gross Income ($thousand), 2009-2014 Table 8.19 Ocata Therapeutic: Regenerative Medicine Clinical Trials, 2015 Table 8.20 Organogenesis: Regenerative Medicine Clinical Trials, 2015 Table 8.21 Osiris Therapeutics: Revenue ($m) and Net Income ($m), 2010-2014 Table 8.22 Osiris Therapeutics: Regenerative Medicine Clinical Trials, 2015 Table 8.23 Pharmicell: Historical Sales ($m, mil.KRW) and Net Income ($m, mil.KRW), 2010-2014 Table 8.24 Regenerys: Regenerative Medicine Clinical Trials, 2015 Table 8.25 TiGenix: Historical Sales (€m, $m) and Net Income (€m, $m), 2011-2014 Table 8.26 TiGenix: Regenerative Medicine Clinical Trials, 2015 Table 8.27 UniQure: Regenerative Medicine Clinical Trials, 2015 Table 8.28 Vericel: Historical Sales ($m and AGR%), 2011-2014 Table 8.29 Vericel: Sales by Product ($m) and Revenue Share (%), 2013-2014 Table 8.30 Vericel Corporation: Regenerative Medicine Clinical Trials, 2015 Table 9.1 SWOT Analysis of the Global Translational Regenerative Medicine Market, 2016-2026 Table 11.1 Global Translational Regenerative Medicine: Market Forecast ($m, CAGR%), 2014, 2018, 2022, 2026 Table 11.2 Global Translational Regenerative Medicine Market: Revenue ($m) and Market Shares (%) by Sector, 2014 Table 11.3 Global Translational Regenerative Medicine Market: Revenue ($m) and Market Shares (%) by Region, 2014, 2020 and 2026 Table 11.4 Global Translational Regenerative Medicine: Market Forecast ($m) by Sector, 2015, 2020 and 2026 Table 11.5 Global Translational Regenerative Medicine Market: Products In Late Stage Development, 2015
List of Figures Figure 1.1 Global Translational Regenerative Medicine Market: Submarkets, 2016 Figure 2.1 Brief History of Stem Cell Research, 1900-2015 Figure 2.2 Examples of FDA-Approved Tissue Engineering Products Figure 2.3 Brief History of Tissue Engineering, 1900-2015 Figure 2.4 Brief History of Gene Therapy, 1970-2015 Figure 3.1 The Global Translational Regenerative Medicine Market: Revenue ($m) by Sector, 2014 and 2015 Figure 3.2 The Gene Therapy Market: Revenue ($m), 2014 and 2015 Figure 3.3 The Global Translational Regenerative Medicine Market Market Forecast: Revenue ($m) and AGR (%),2014-2026 Figure 3.4 The Global Translational Regenerative Medicine Market Forecast: CAGR (%) by Sector, 2014-2020 Figure 3.5 The Global Translational Regenerative Medicine Market Forecast: CAGR (%) by Sector, 2020-2026 Figure 3.6 The Global Translational Regenerative Medicine Market Forecast: CAGR (%) by Sector, 2014-2026 Figure 3.7 The Global Translational Regenerative Medicine Market: Revenue ($m) by Sector, 2014, 202 0 and 2026 Figure 3.8 The Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2014 Figure 3.9 The Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2020 Figure 3.10 The Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2026 Figure 4.1 Global Stem Cell Therapies Market Forecast: Revenue ($m) and AGR (%),2014-2026 Figure 4.2 Osteocel Plus Sales Forecast: Revenue ($m) and AGR (%), 2014-2026 Figure 4.3 Trinity ELITE Sales Forecast: Revenue ($m) and AGR (%), 2014-2026 Figure 4.4 TEMCELL / Prochymal Sales Forecast: Revenue ($m) and AGR (%), 2014-2026 Figure 4.5 Stem Cell Therapies: Drivers and Restraints, 2016-2026 Figure 5.1 Global Tissue Engineering Therapies Market Forecast: Revenue ($m) and AGR (%),2014-2026 Figure 5.2 Apligraf Sales Forecast: Revenue ($m) and AGR (%), 2014-2026 Figure 5.3 Dermagraft Sales Forecast: Revenue ($m) and AGR (%), 2014-2026 Figure 5.4 ReCell Sales Forecast: Revenue ($m) and AGR (%), 2014-2026 Figure 5.5 Tissue Engineered Therapy Products: Drivers and Restraints, 2016-2026 Figure 6.1 Global Gene Therapies Market Forecast: Revenue ($m) and AGR (%),2014-2026 Figure 6.2 Neovasculgen Sales Forecast: Revenue ($m) and AGR (%), 2014-2026 Figure 6.3 Glybera Sales Forecast: Revenue ($m) and AGR (%), 2014-2026 Figure 6.4 Talimogene Laherparepvec (IMLYGIC) Sales Forecast: Revenue ($m) and AGR (%), 2014-2026 Figure 6.5 Gene Therapy Products: Market Drivers and Restraints, 2016-2026 Figure 7.1 The Global Translational Regenerative Medicine Market: Market Size ($m) by Region, 2014 and 2015 Figure 7.2 Asia-Pacific, Europe, US, and ‘Rest of the World’ Translational Regenerative Medicine Market: Market Forecast ($m), 2014-2026 Figure 7.3 Global Translational Regenerative Medicine Market: CAGR (%) by Region, 2014-2020 Figure 7.4 Global Translational Regenerative Medicine Market: CAGR (%) by Region, 2020-2026 Figure 7.5 Global Translational Regenerative Medicine Market: CAGR (%) by Region, 2014-2026 Figure 7.6 Global Translational Regenerative Medicine Market: Market Share (%) by Region, 2014 Figure 7.7 Global Translational Regenerative Medicine Market: Market Share (%) by Region, 2020 Figure 7.8 Global Translational Regenerative Medicine Market: Market Share (%) by Region, 2026 Figure 7.9 US Translational Regenerative Medicine: Market Drivers and Restraints, 2016-2026 Figure 7.10 US Translational Regenerative Medicine Market Market Forecast: Revenue ($m) and AGR (%),2014-2026 Figure 7.11 European Translational Regenerative Medicine: Market Drivers and Restraints, 2016-2026 Figure 7.12 European Translational Regenerative Medicine Market Market Forecast: Revenue ($m) and AGR (%),2014-2026 Figure 7.13 Asia-Pacific Translational Regenerative Medicine: Market Drivers and Restraints, 2016-2026 Figure 7.14 Asia-Pacific Translational Regenerative Medicine Market Market Forecast: Revenue ($m) and AGR (%),2014-2026 Figure 7.15 Rest of the World Translational Regenerative Medicine Market Market Forecast: Revenue ($m) and AGR (%),2014-2026 Figure 8.1 Alphatec Spine: Historical Sales ($m) and Operating Loss ($m), 2009-2014 Figure 8.2 Athersys: Historical Sales ($m) 2010-2014 Figure 8.3 Athersys: Historical Revenue, Expenditure and Losses ($m) 2010-2014 Figure 8.4 Avita Medical: Historical Sales ($m, AUD m) and Net Loss ($m, AUD m), 2013-2014 Figure 8.5 AxoGen: Historical Sales ($m) and Net Loss ($m), 2010-2014 Figure 8.6 Medipost: Historical Sales ($m, mil.KRW) and Net Income ($m, mil.KRW), 2010-2014 Figure 8.7 Medipost: Revenue Share by Business Area (%), 2012 Figure 8.8 Medipost: Revenue Share by Business Area (%), 2013 Figure 8.9 Medipost: Revenue Share by Business Area (%), 2014 Figure 8.10 Mesoblast: Historical Sales ($m, AUD m), 2011-2014 Figure 8.11 NuVasive: Historical Sales and Net Income (Profits and Losses) ($m), 2009-2014 Figure 8.12 Ocata Therapeutics: Historical Sales ($thousand) and Gross Income ($thousand), 2009-2014 Figure 8.13 Osiris Therapeutics: Revenue ($m) and Net Income ($m), 2010-2014 Figure 8.14 Pharmicell: Historical Sales (mil.KRW) and Net Income (mil.KRW), 2010-2014 Figure 8.15 TiGenix: Historical Sales ($m) and Net Income ($m), 2011-2014 Figure 8.16 Vericel: Historical Sales ($m), 2011-2014 (Limited Scale) Figure 8.17 Vericel: Historical Sales ($m), 2011-2014 (Full Scale) Figure 8.18 Vericel: Revenue Contribution by Product (%) 2014 Figure 9.1 Porter’s Five Force Analysis of the Translational Regenerative Medicine Market, 2016 Figure 11.1 Global Translational Regenerative Medicine: Market Forecast ($m), 2014, 2020 and 2026 Figure 11.2 Global Translational Regenerative Medicine Market: Market Share (%) by Sector, 2014 Figure 11.3 Global Translational Regenerative Medicine: Market Forecast ($m) by Sector, 2014-2026
Advanced BioHealing Advanced Tissue Sciences Advantagene AlloSource AlphaTec Spine Amedica Amgen Amorcyte Amorepacific Group AnGes MG Angioblast Systems Anika Therapeutics Anterogen Apceth Arcarios B.V Ark Therapeutics Athersys Inc Avita Medical AxoGen Baxter Beike Biotechnology Benda Pharmaceutical BioD Bioheart BioMed Realty Trust, Inc BioSante Pharmaceuticals BioTime BioTissue AG BioVex Inc Blackstone Medical BrainStorm Cell Therapeutics Caladrius Biosciences California Stem Cell Inc Capricor Cardio3BioSciences Celgene Cell Targeting CellCo Tec Cellerant Therapeutics Cephalon Ceregene CHA Biotech Chiesi Farmaceutici Cipla Co.don AG Cold Genesys Cook Biotech Inc Cytomedix Cytori Therapeutics Daiichi Sankyo DePuy Mitek (Johnson & Johnson) FibroCell Science Gamida Cell Ltd Genzyme Corporation (Sanofi) Histogenics Humacyte Human Stem Cell Institute Insulete Inc Interxon Corporation ISTO Technologies Janssen Biotech Inc Japan Tissue Engineering Co JCR Pharmaceuticals Johnson & Johnson Kinetic Concept Inc LecTec Corporation Lincoln Park Capital Lonza MacroCure Medipost Medtronic Mesoblast Mitsubishi Tanabe Myriad Genetics Neostem Neuralstem Nippon Zoki Pharmaceuticals NuVasive Ocata Therapeutics OncoCyte Organovo Orphan Biovitrum AB (Sobi) Orthofix Orteq Ltd. Osiris Therapeutics Oxford BioMedica Parcell Laboratories Pfizer Pharmicell Regenerys Reliance Life Sciences ReNeuron RTI Surgical Rusnano Corporation Sangamo Biosciences Sanofi Shanghai Sunway Biotech Shenzhen Sibiono GeneTech Shire Singapore General Hospital Skye Orthobiologics Smith & Nephewbv Sobi Partners Spark Therapeutics StemCells Inc. Stempeutics Research Stratatech Corporation TCA Cellular Therapy Tengion Inc Teva Pharmaceuticals TiGenix UniQure U.S. Stem Cell Inc. Vericel Corporation Viacyte Inc Vital Therapies WKD Holding Oy Xcellerex Xenetic Biosciences Zimmer
Organisations Mentioned in the Report Arthritis Research UK Associazione Infermieristica per lo Studio delle Lesioni Cutanee (AISLeC) [China] Australian Regenerative Medicine Institute Australian Sports Anti-Doping Authority (ASADA) Biomedical Advanced Research and Development Authority (BARDA) British Heart Foundation [UK] California Institute of Regenerative Medicine (CIRM) Cambridge Stem Cell Biology Institute [UK] Case Western Reserve University Catalan Institution for Research and Advanced Studies Center for Biologics Evaluation and Research (CBER) [US] CHA General Hospital [Korea] Cryocenter Saint Petersburg Drugs Controller General of India (DCGI) European Group for Blood and Marrow Transplantation (EBMT) European Medicines Agency Food and Drugs Agency (FDA) [US] Haute Autorité de santé [France] Heriot-Watt University Human Fertilisation and Embryology Authority (HFEA) Institute of Biomedical Research and Innovation Hospital [Japan] International Society for Stem Cell Research (ISSCR) Karolinska Institute [Sweden] Massachusetts General Hospital (MGH) Mayo Clinic [US] Medical Research Council [UK] Ministry of Food and Drug Safety, MFDS) [Korea] Ministry of Health, Labour and Welfare (MHLW) [Japan] Ministry of Science and Technology [China] Moorfields Eye Hospital National Tissue Engineering Center (NTEC) [China] New York Blood Center Riken Center for Developmental Biology RUSH University Medical Center [US] Russian Ministry of Healthcare and Social Development Scottish Centre for Regenerative Medicine St. Jude’s Children Research Hospital State Food and Drug Administration (SFDA) [China] SUNY Upstate Medical University The Genetico Center [Russia] The StemGen Organisation Therapeutics Goods Administration (TGA) [Australia] UH San Diego Sanford Stem Cell Clinical Center UK Medicines and Healthcare Products Regulatory Agency (MHRA) Universitat Autònoma de Barcelona [Spain] University College London University of Edinburgh MRC Centre for Regenerative Medicine [UK] University of Massachusetts (UMass) Memorial Hospital University of Modena Centre for Regenerative Medicine [Italy] University of Wisconsin US National Institute of Health Wake Forest Institute Wellcome Trust World Health Organization Yale School of Medicine
Download sample pages
Complete the form below to download your free sample pages for Translational Regenerative Medicine: Market Prospects 2016-2026
Download sample pages
Complete the form below to download your free sample pages for Translational Regenerative Medicine: Market Prospects 2016-2026
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.
The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet
The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.
Rising epidemic potential, a growing emphasis on therapeutic vaccines, and new markets are projected to provide considerable growth prospects for vaccine providers.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
